Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1040 participants.
Also called NCT07682922
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,040 participants
- Registry
-
NCT07682922
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07682922. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2028-07-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS)
- Acronym
- SLEDAIS
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Edaravone dexborneol sublingual tablet
- Intervention (Drug)
- Placebo
- Lead sponsor
- Xinqiao Hospital of Chongqing
- Collaborator
- Simcere Pharmaceutical Group Co., LTD
Record details
- Record id
cardio:ct-nct07682922- Content hash
2733c3c1df33cce5de2a210a874033d9c80024faf313ecc018ca9c8b77e74e39